A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: The Brazilian cystic fibrosis multicenter study;O impacto de primeiro ano de tratamento com dornase alfa nos parâmetros clínicos de pacientes com fibrose cística: Estudo multicêntrico brasileiro

Revista Paulista de Pediatria

Volumn 31, Issue 4, 2013, Pages 420-430

  Rozov, Tatiana ^a   e Silva, Fernando Antônio A ^b   Santana, Maria Angélica ^c   Adde, Fabíola Villac ^d   Mendes, Rita Heloisa ^e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Secretaria da Saude do Estado da Bahia   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e HOSPITAL DE BASE DO DISTRITO FEDERAL   (Brazil)

Author keywords

Clinical evolution; Cystic fibrosis; Dornase alfa; Pulmonary microbiology; Therapeutics

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DORNASE ALFA; PANCREAS ENZYME; VITAMIN; DEOXYRIBONUCLEASE I; RECOMBINANT PROTEIN;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; CHILD; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; EMERGENCY HEALTH SERVICE; EXERCISE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; OXYGEN SATURATION; PHYSIOTHERAPY; PSEUDOMONAS AERUGINOSA; QUESTIONNAIRE; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; BRAZIL; CLINICAL TRIAL; MULTICENTER STUDY; PROSPECTIVE STUDY; TIME;

ADOLESCENT; BRAZIL; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; HUMANS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 84892610124     PISSN: 01030582     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0103-05822013000400002     Document Type: Article

References (33)

1. Cystic Fibrosis Foundation [homepage on the Internet]. Patient Registry 2009: annual report [cited 2011 Sep 20]. Available from: http://www.cff.org/UploadedFiles/research/ClinicalResearch/Patient-Registry-Report-2009.pdf
2. Flume PA. Pulmonary complications of cystic fibrosis. Respir Care 2009;54:618-27.
3. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73.
4. Padman R, Passi V. Cystic fibrosis overview and update on infant care. OJPed 2012;2:187-96.
5. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69.
6. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571-2.
7. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-14.
8. Orenstein DM, Winnie GB, Altman H. Cystic fibrosis: a 2002 update. J Pediatr 2002;140:156-64.
9. Alvarez AE, Ribeiro AF, Hessel G, Bertuzzo CS, Ribeiro JD. Cystic fibrosis at a Brazilian center of excellence: clinical and laboratory characteristics of 104 patients and their association with genotype and disease severity. J Pediatr (Rio J) 2004;80:371-9.
10. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
11. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 1990;87:9188-92.
12. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
13. 1 decline in cystic fibrosis. Pediatr Pulmonol 2011;46:545-53.
14. Rozov T, de Oliveira VZ, Santana MA, Adde FV, Mendes RH, Paschoal IA et al. Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis-a one-year prospective study. Pediatr Pulmonol 2010;45:874-82.
15. Rozov T, Cunha MT, Nascimento O, Quittner AL, Jardim JR. Linguistic validation of cystic fibrosis quality of life questionnaires. J Pediatr (Rio J) 2006;82:151-6.
16. Henry B, Aussage P, Grosskopf C, Goehrs JM, Launois R; the French CFQOL Study Group. Cystic fibrosis questionnaire (CFQ); Cystic Fibrosis Questionnaire Revised (CFQ-R). English version 2.0 [CD-ROM]. Miami: University of Miami; 2004.
17. Heijerman H, Westerman E, Conway S, Touw D, Döring G; Consensus Working Group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8:295-315.
18. Abbott J, Hart A. Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review. Health Qual Life Outcomes 2005;3:19.
19. o 224, de 10 de maio de 2010. Protocolos clínicos e diretrizes terapêuticas na fibrose cística-manifestações pulmonares. Ministério da Saúde; 2010.
20. Grupo Brasileiro de Estudos de Fibrose Cística [homepage on the Internet]. Registro Brasileiro de Fibrose Cística: primeiro relatório anual-ano 2009 [cited 2013 Feb 21]. Available from: http://www.gbefc.org.br/gbefc/estudo_gbefc_2009.pdf
21. Raskin S, Pereira-Ferrari L, Reis FC, Abreu F, Marostica P, Rozov T et al. Incidence of cystic fibrosis in five different states of Brazil as determined by screening of p. F508del, mutation at the CFTR gene in newborns and patients. J Cyst Fibros 2008;7:15-22.
22. Gangell C, Gard S, Douglas T, Park J, de Klerk N, Keil T et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 2011;53:425-32.
23. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002;17:47-56.
24. Steinkamp G, Wiedemann B, Rietschel E, Krahl A, Gielen J, Bärmeier H et al. Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibros 2005;4:41-8.
25. Bonestroo HJ, Slieker MG, Arets HG. No positive effect of rhdnase on the pulmonary colonization in children with cystic fibrosis. Monaldi Arch Chest Dis 2010;73:12-7.
26. Frederiksen B, Pressler T, Hansen A, Koch C, Høiby N. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 2006;95:1070-4.
27. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-20.
28. Sawicki GS, Rasouliyan L, McMullen AH, Wagener JS, McColley SA, Pasta DJ et al. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol 2011;46:36-44.
29. Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2010(3):CD001127 [cited 2013 Feb 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20238314
30. 1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46:393-400.
31. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008;153:752-7.
32. Clarke SA, Eiser C. The measurement of health-related quality of life (QOL) in paediatric clinical trials: a systematic review. Health Qual Life Outcomes 2004;2:66.
33. Shah PL, Conway S, Scott SF, Rainisio M, Wildman M, Stableforth D et al. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Respiration 2001;68:160-4.